The reversal removes a favorable judgment and exposes Intuitive to a new trial on antitrust claims that could result in treble damages, injunctive relief on EndoWrist repair restrictions, and follow-on private lawsuits from hospitals and other third-party servicers. Monitor for settlement discussions, further appellate activity (en banc or certiorari), and any FDA or FTC involvement. The stock may face overhang until the litigation risk is resolved.
Price Chart
Executive Summary
The Ninth Circuit reversed the district court's judgment in favor of Intuitive Surgical in an antitrust case brought by Surgical Instrument Service Company (SIS). The appellate panel held that the lower court erred by requiring SIS to prove the 'Kodak/Epic factors' because SIS presented evidence that Intuitive possesses >99% market share in the foremarket for MIST surgical robots, making this a standard foremarket/aftermarket tying claim rather than a Kodak-style claim. The case is remanded for a new trial, reopening antitrust exposure for Intuitive's EndoWrist aftermarket restrictions and third-party repair policies.
Court Ruling Details
Key Facts
- Ninth Circuit reversed district court judgment in favor of Intuitive Surgical in antitrust case SIS v. Intuitive Surgical.
- Panel held that the Kodak/Epic factors do not apply when the defendant possesses market power in the foremarket (Intuitive has >99% share in MIST surgical robots).
- SIS presented evidence that Intuitive leveraged its near-100% foremarket share to maintain 100% aftermarket share in EndoWrist instruments.
- Case remanded for new trial on SIS's antitrust claims (tying, exclusive dealing, monopolization, attempted monopolization).
- Intuitive's argument that evidence was insufficient was rejected; the court found sufficient evidence of pre-2019 market power and an illusory third-party approval process.
Financial Impact
Antitrust exposure reopened; potential for treble damages, injunctive relief on EndoWrist aftermarket restrictions, and follow-on private suits. No specific damages amount stated in the opinion.
Risk Factors
- Potential treble damages and injunctive relief on EndoWrist aftermarket restrictions
- Follow-on private antitrust suits from hospitals and other repair companies
- Regulatory scrutiny from FTC (filed amicus brief supporting SIS) and potential FDA involvement
- Uncertainty over duration of new trial and appeal timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-206144f6d8-ISRG |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 11d ago | ANALYST-UPGRADE | $414.52 $422.06 | ▲ +1.82% | ▲ +1.72% | $426.70 (+2.94%) |
Sep 16, 2026 4w ago | Insider Cluster | $382.29 $398.30 | ▲ +4.19% | ▲ +1.62% | $426.70 (+11.62%) |
Aug 19, 2026 8w ago | Insider Cluster | $374.48 $367.07 | ▼ −1.98% | ▼ −3.09% | $426.70 (+13.94%) |
Aug 13, 2026 9w ago | Court Ruling | $401.27 $374.48 | ▲ +6.68% | ▲ +4.71% | $426.70 (−6.34%) |
Aug 12, 2026 9w ago | ANALYST-UPGRADE | $401.27 $397.72 | ▼ −0.88% | ▼ −0.44% | $426.70 (+6.34%) |
Aug 12, 2026 9w ago | Insider Cluster | $401.27 $397.72 | ▼ −0.88% | ▼ −0.44% | $426.70 (+6.34%) |
Aug 11, 2026 9w ago | Insider Cluster | $401.27 $397.72 | ▼ −0.88% | ▼ −0.44% | $426.70 (+6.34%) |
Jul 30, 2026 11w ago | ANALYST-DOWNGRADE | $352.97 $373.71 | ▲ +5.88% | ▲ +2.25% | $426.70 (+20.89%) |
Jul 16, 2026 13w ago | Press Release | $345.42 $332.02 | ▼ −3.88% | ▼ −3.19% | $426.70 (+23.53%) |
Jul 9, 2026 14w ago | ANALYST-UPGRADE | $411.55 $402.33 | ▼ −2.24% | ▼ −2.11% | $426.70 (+3.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access